A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

Journal of Translational Medicine

Research

Henrik Schmidt¹  Michele Guida²  Henry Gómez³  Steinar Aamdal⁴  Johan Hansson⁵  Aviram Nissan⁶  David M Hyams⁷  Lars Bastholt⁸  Scott D Chasalow⁹  Laura Ridolfi^1,10  Omid Hamid^1,11  David Berman^1,12 

[1] Department of Clinical Medicine and Department of Oncology, Aarhus University Hospital, (Nørrebrogade 44), (DK-8000), Aarhus C, Denmark;Department of Medical Oncology, National Institute of Cancer, (Viale Orazio Flacco 65), (70124), Bari, Italy;Department of Medicine, Instituto Nacional de Enfermedades Neoplásicas, (Avenida Angamos, Este 2520), (34), Lima, Perú;Department of Oncology, Section for Clinical Cancer Research, Oslo University Hospital, (Ullernchausseen 70, OUS Radiumhospitalet), (0310), Oslo, Norway;Department of Oncology-Pathology, Karolinska Institutet and Karolinska University Hospital Solna, (SE-171), (77), Stockholm, Sweden;Department of Surgery, Hadassah Hebrew University Medical Center, (P.O.Box 24035), (il-91240), Jerusalem, Israel;Desert Surgical Oncology, (39000 Bob Hope Drive), (92270), Rancho Mirage, USA;EORTC Melanoma Group, Odense University Hospital, (Sdr. Boulevard 29), (DK-5000), Odense, Denmark;Exploratory Development, Global Biometric Sciences, Bristol-Myers Squibb Company, (Route 206 & Province Line Rd), (08543), Princeton, USA;Immunotherapy Unit, IRST Cancer Institute, (Via P. Maroncelli 40), (47014), Meldola, Italy;Melanoma Center, The Angeles Clinic and Research Institute, (2001 Santa Monica Blvd), (90404), Santa Monica, USA;Research and Development, Discovery Medicine, Bristol-Myers Squibb Company, (Route 206 & Province Line Rd), (08543), Princeton, USA;

关键词: Cytotoxic T-lymphocyte antigen-4;    FoxP3;    indoleamine 2,3-dioxygenase;    ipilimumab;    melanoma;    tumor biomarker;    tumor-infiltrating lymphocytes;   

DOI  :  10.1186/1479-5876-9-204

 received in 2010-12-14, accepted in 2011-11-28,  发布年份 2011

来源: Springer

【 摘 要 】

BackgroundIpilimumab, a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4, has demonstrated an improvement in overall survival in two phase III trials of patients with advanced melanoma. The primary objective of the current trial was to prospectively explore candidate biomarkers from the tumor microenvironment for associations with clinical response to ipilimumab.MethodsIn this randomized, double-blind, phase II biomarker study (ClinicalTrials.gov NCT00261365), 82 pretreated or treatment-naïve patients with unresectable stage III/IV melanoma were induced with 3 or 10 mg/kg ipilimumab every 3 weeks for 4 doses; at Week 24, patients could receive maintenance doses every 12 weeks. Efficacy was evaluated per modified World Health Organization response criteria and safety was assessed continuously. Candidate biomarkers were evaluated in tumor biopsies collected pretreatment and 24 to 72 hours after the second ipilimumab dose. Polymorphisms in immune-related genes were also evaluated.ResultsObjective response rate, response patterns, and safety were consistent with previous trials of ipilimumab in melanoma. No associations between genetic polymorphisms and clinical activity were observed. Immunohistochemistry and histology on tumor biopsies revealed significant associations between clinical activity and high baseline expression of FoxP3 (p = 0.014) and indoleamine 2,3-dioxygenase (p = 0.012), and between clinical activity and increase in tumor-infiltrating lymphocytes (TILs) between baseline and 3 weeks after start of treatment (p = 0.005). Microarray analysis of mRNA from tumor samples taken pretreatment and post-treatment demonstrated significant increases in expression of several immune-related genes, and decreases in expression of genes implicated in cancer and melanoma.ConclusionsBaseline expression of immune-related tumor biomarkers and a post-treatment increase in TILs may be positively associated with ipilimumab clinical activity. The observed pharmacodynamic changes in gene expression warrant further analysis to determine whether treatment-emergent changes in gene expression may be associated with clinical efficacy. Further studies are required to determine the predictive value of these and other potential biomarkers associated with clinical response to ipilimumab.

【 授权许可】

CC BY   
© Hamid et al; licensee BioMed Central Ltd. 2011